Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Hematology

Cracking the Code: Your Lab and Pathology Reports

At a Glance

When reviewing Polycythemia Vera (PV) lab results, the most critical number is the hematocrit, which should be kept at or below 45% to prevent blood clots. Your pathology report will also detail your JAK2 mutation allele burden and bone marrow activity to help guide your ongoing care.

When you look at your medical records, you will likely see two main types of reports: the Complete Blood Count (CBC), which tracks your blood levels, and the Pathology Report, which describes your bone marrow and genetics. Understanding these terms can help you track your progress and have more productive conversations with your doctor.

Decoding Your Blood Work (CBC)

The CBC is the most frequent test you will have. It monitors the “thickness” of your blood and the activity of your bone marrow [1].

  • Hematocrit (HCT): This is the most critical number for a PV patient. It measures the percentage of your blood that is made of red blood cells [2].
    • The Goal: For most patients, the target is to keep HCT ≤45%. Keeping HCT below this level is the best way to reduce the risk of blood clots [3][4].
  • Hemoglobin (HGB): This measures the protein in your red blood cells that carries oxygen. Like HCT, it will be elevated in PV because your body is making too many red cells [2].
  • White Blood Cells (WBC) and Platelets: Because PV affects the “parent” cells in the bone marrow, many patients also have high levels of white blood cells and platelets. This overproduction of all three types of cells is a common feature of the disease [2][5].

Decoding Your Bone Marrow Report

A bone marrow biopsy provides a “snapshot” of the factory where your blood is made. Pathologists use specific terms to describe what they see under the microscope [5].

  • Hypercellularity: This means your bone marrow is more “crowded” with cells than it should be for your age. In PV, the marrow is working overtime [6][7].
  • Panmyelosis: This is a hallmark of PV. It means there is an abnormal increase in all three “lines” of blood cells: red cells, white cells, and platelets [5][8].
  • Megakaryocytes: These are the large cells in the marrow that produce platelets. In PV, a pathologist looks at the shape and size of these cells to help distinguish PV from other similar blood disorders [9][10].

Decoding Your Genetic Reports

Your report may include specialized molecular testing to look at the mutations driving the disease.

  • JAK2 V617F Allele Burden: This is the “dose” or percentage of your blood cells that carry the JAK2 mutation [11]. For example, a 50% allele burden means half of your blood cells are clones from the PV mutation. Monitoring this over time can help doctors see how well certain treatments are working [12][13].
  • DTA Mutations (DNMT3A, TET2, ASXL1): These are “additional” mutations sometimes found alongside JAK2.
    • TET2: Common in PV and may increase the risk of blood clots [14].
    • ASXL1: This is sometimes checked because its presence can suggest a higher risk for the disease to progress or change over time [15][16].

Lab Result Checklist

When you receive your reports, ensure you can find these key pieces of information:

  • [ ] Hematocrit (HCT): Is it currently at or below 45%? [3]
  • [ ] JAK2 Status: Is it V617F or Exon 12? [17]
  • [ ] Allele Burden: Is the percentage listed in your molecular report? [11]
  • [ ] Fibrosis Grade: Does the biopsy mention “reticulin” or “fibrosis”? (Often graded 0 to 3) [8]
  • [ ] EPO Level: Was it low or suppressed at diagnosis? [10]

Common questions in this guide

What is a safe hematocrit level for polycythemia vera?
For most patients with polycythemia vera, the goal is to keep hematocrit at or below 45 percent. Maintaining this level is the best way to reduce your risk of experiencing dangerous blood clots.
What does JAK2 V617F allele burden mean on my lab report?
The JAK2 allele burden refers to the percentage of your blood cells that carry the JAK2 mutation. Doctors monitor this number over time to see how active the disease is and how well your current treatments are working.
What does hypercellularity mean on a bone marrow biopsy?
Hypercellularity means your bone marrow is more crowded with cells than is normal for a person your age. In polycythemia vera, this happens because the bone marrow is in overdrive and overproducing blood cells.
What is panmyelosis?
Panmyelosis is a hallmark feature of polycythemia vera. It means there is an abnormal increase in the production of all three main types of blood cells, which include red cells, white cells, and platelets.
Why do doctors test for DTA mutations like TET2 or ASXL1?
These are additional genetic mutations that are sometimes found alongside the primary JAK2 mutation. Testing for them helps your doctor understand your specific risk for blood clots and the likelihood of your disease progressing over time.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my JAK2 V617F allele burden (percentage) at the time of diagnosis?
  2. 2.My report mentions 'hypercellularity'—how does my marrow's activity level compare to what is normal for my age?
  3. 3.Does my bone marrow biopsy show any signs of fibrosis or scarring?
  4. 4.Why did we test for 'DTA' mutations like ASXL1 or TET2, and what do those results mean for my long-term outlook?
  5. 5.What is my current hematocrit target, and how often will we check my CBC to make sure we stay below that?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.

    Gordeuk VR, Key NS, Prchal JT

    Haematologica 2019; (104(4)):653-658 doi:10.3324/haematol.2018.210732.

    PMID: 30872370
  2. 2

    Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.

    Tefferi A, Barbui T

    American journal of hematology 2023; (98(9)):1465-1487 doi:10.1002/ajh.27002.

    PMID: 37357958
  3. 3

    Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera.

    Benevolo G, Marchetti M, Melchio R, et al.

    Vascular health and risk management 2023; (19()):765-778 doi:10.2147/VHRM.S429995.

    PMID: 38025519
  4. 4

    Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.

    Gerds AT, Mesa R, Burke JM, et al.

    Blood 2024; (143(16)):1646-1655 doi:10.1182/blood.2023020232.

    PMID: 38142448
  5. 5

    Polycythemia vera.

    Ellis MH, Barbui T, Tefferi A

    Mayo Clinic proceedings 2026; (101(5)):826-845 doi:10.1016/j.mayocp.2026.01.008.

    PMID: 41902804
  6. 6

    Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.

    Kuykendall AT

    Annals of hematology 2023; (102(5)):985-993 doi:10.1007/s00277-023-05172-y.

    PMID: 36944847
  7. 7

    Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.

    Yacoub A, Mascarenhas J, Kosiorek H, et al.

    Blood 2019; (134(18)):1498-1509 doi:10.1182/blood.2019000428.

    PMID: 31515250
  8. 8

    Macroscopic Hematuria as the Initial Presentation of Polycythemia Vera.

    Oliveira SCS, Santos LTR, Esmeraldo MA, et al.

    Cureus 2020; (12(10)):e10800 doi:10.7759/cureus.10800.

    PMID: 33163304
  9. 9

    Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm.

    Ghai S, Rai S

    South Asian journal of cancer 2017; (6(2)):75-78 doi:10.4103/2278-330X.208854.

    PMID: 28702412
  10. 10

    Update from the latest WHO classification of MPNs: a user's manual.

    Passamonti F, Maffioli M

    Hematology. American Society of Hematology. Education Program 2016; (2016(1)):534-542 doi:10.1182/asheducation-2016.1.534.

    PMID: 27913526
  11. 11

    The Janus kinase 2 (JAK2) Mutation Burden is Related to Hematological Outcomes in Thai Patients with Myeloproliferative Neoplasms.

    Sritana N, Cholnakasem N, Yimyaem M, et al.

    Asian Pacific journal of cancer prevention : APJCP 2025; (26(2)):579-586 doi:10.31557/APJCP.2025.26.2.579.

    PMID: 40022704
  12. 12

    The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation.

    Brown R, Bennett R, Crean C, et al.

    British journal of haematology 2025; (207(6)):2597-2601 doi:10.1111/bjh.70198.

    PMID: 41132056
  13. 13

    Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety.

    Masarova L, Mascarenhas J, Rampal R, et al.

    Cancer 2025; (131(1)):e35661 doi:10.1002/cncr.35661.

    PMID: 39616447
  14. 14

    Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations.

    Segura-Díaz A, Stuckey R, Florido Y, et al.

    Cancers 2020; (12(4)) doi:10.3390/cancers12040934.

    PMID: 32290079
  15. 15

    Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.

    Wang Z, Liu W, Wang M, et al.

    Annals of hematology 2021; (100(2)):465-479 doi:10.1007/s00277-020-04387-7.

    PMID: 33386934
  16. 16

    ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms.

    Shi Z, Liu J, Zhao Y, et al.

    Haematologica 2023; (108(5)):1359-1373 doi:10.3324/haematol.2021.280320.

    PMID: 36005555
  17. 17

    Hemochromatosis, Erythrocytosis and the JAK2 p.V617F Mutation.

    Langabeer SE

    EJIFCC 2017; (28(1)):92-93.

    PMID: 28439222

This page explains Polycythemia Vera lab and pathology terminology for educational purposes only. Always consult your hematologist or oncologist to interpret your specific reports and lab results.

Get notified when new evidence is published on Polycythemia vera.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.